Humulin R Cartridge (Insulin Human (Rdna))

Humulin R Cartridge is indicated for the management of blood glucose levels in patients with diabetes who require short‑acting insulin therapy. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other glucose‑lowering agents.

• Initiates rapid reduction of post‑prandial blood glucose.
• Suitable for mealtime dosing in type 1 diabetes.
• Used when basal insulin alone does not achieve target glycemia in type 2 diabetes.
• Can be combined with long‑acting insulin analogues for basal‑bolus regimens.
• Administered via insulin pen for precise dose adjustment.

• Humulin R delivers recombinant human insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. These actions collectively lower circulating glucose concentrations within minutes after injection.

Adverse reactions to Humulin R Cartridge can vary in frequency and severity; they are typically categorized as common or serious.

Common

• Mild hypoglycemia presenting as shakiness, sweating, hunger, or irritability.
• Injection‑site reactions such as redness, swelling, itching, or bruising.
• Lipodystrophy characterized by localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at the injection site.
• Transient weight gain often observed with improved glycemic control and fluid retention.

Serious

• Severe hypoglycemia with loss of consciousness, seizures, or need for assistance from another person.
• Allergic reactions ranging from urticaria and angioedema to life‑threatening anaphylaxis.
• Persistent hyperglycemia or ketoacidosis suggesting inadequate insulin effect or dosing error.

Most patients experience only mild symptoms, but monitoring is essential.

When using Humulin R Cartridge, several precautions should be observed to minimize risks and ensure optimal therapeutic outcomes.

• Verify the cartridge is intact, not expired, and stored according to label instructions.
• Rotate injection sites to reduce the risk of lipodystrophy and improve absorption.
• Adjust dose based on carbohydrate intake, physical activity, and blood glucose monitoring.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in individuals with known hypersensitivity to recombinant human insulin or any excipients.

Humulin R Cartridge may interact with other medicines, affecting blood glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase the risk of low blood glucose.
• Corticosteroids or thiazide diuretics, which can raise glucose levels and require insulin dose changes.
• Alcohol consumption, which can cause delayed hypoglycemia after insulin administration.